Compare Flagstar Bank NA (FLG) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FLG trades at $11.21, down 0.88% with a bearish technical outlook despite recent earnings beats in Q4 2025 and Q1 2026. The stock shows mixed fundamentals with a low P/B ratio of 0.61x but elevated P/E of 373.67x, while profitability metrics remain weak with net income margin at 2.3%. Recent news highlights strategic partnerships and a $250 million share repurchase program, though Q2 2026 earnings missed expectations.

Wall Street maintains a bullish consensus with 60% buy ratings and a $16.81 price target, representing 50% upside potential. Key risks include volatile earnings performance, high valuation multiples, and negative cash flow trends. The company's turnaround efforts and strong capital position provide potential catalysts, but execution risks remain significant.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.